Japanese collaboration agreement extended to allow final evaluation of performance on clinical samples
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Japanese collaboration agreement extended to allow final evaluation of performance on clinical samples

In December 2019, AcouSort announced that the company had signed an agreement with a major Japanese industrial player regarding the lease of one AcouWash system and accompanying application support. The system has been used for sample preparation in an R&D project aiming to develop and evaluate the potential of a new diagnostic assay. The evaluation is now in its final phase, where the new assay will be tested using clinical samples.

Over the past years, AcouSort has worked very closely with the Japanese company's research team and successfully helped them to optimize their cell separation application required to enable the development of the new diagnostic test. During 2022, AcouSort and the Japanese partner finalized the application optimization of the sample preparation part. In parallel, the Japanese team finalized the development of the assay. The Japanese company has now extended the lease of the AcouWash system to evaluate the complete assay workflow on clinical samples. Once this evaluation is finalized, the Japanese company will start an internal review process to evaluate the business potential and decide whether to initiate a product development project.

The company has been very satisfied with the AcouWash sample preparation, which gives a higher sample quality and is significantly more stable than the centrifugation-based method they initially used.

 

“At AcouSort, we have been very happy with this great collaboration with a world-leading life science company. That the Japanese company has chosen to work with our technology in their assay development, and that the project now has reached the phase where clinical samples will be evaluated, is a great seal of approval. This project is in-line with our long-term strategy; to establish our acoustofluidic technology as the gold standard for providing integrated sample preparation in diagnostic and therapeutic instrumentation. ,” says AcouSort’s CEO Torsten Freltoft.

 

Bifogade filer

Nyheter om AcouSort

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien AcouSort

Senaste nytt